This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Immodulon Therapeutics Limited. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Kevin Bilyard: Innovator in Cancer Therapy
Introduction
Kevin Bilyard is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer therapy, holding a total of 6 patents. His work focuses on developing innovative immunomodulators that enhance the effectiveness of cancer treatments.
Latest Patents
Among his latest patents is a groundbreaking checkpoint inhibitor designed for use in cancer therapy. This immunomodulator aims to treat, reduce, inhibit, or control neoplastic diseases in patients undergoing checkpoint inhibition therapy. The invention allows for simultaneous, separate, or sequential administration of the immunomodulator, which preferably comprises a whole cell.
Career Highlights
Kevin Bilyard has established himself as a key figure in the biotechnology sector. He is currently associated with Immodulon Therapeutics Limited, where he continues to advance research in cancer treatment. His innovative approaches have garnered attention and respect within the scientific community.
Collaborations
Throughout his career, Kevin has collaborated with notable professionals, including Charles Akle and John Grange. These partnerships have contributed to the development of his patents and the advancement of cancer therapy.
Conclusion
Kevin Bilyard's work in cancer therapy exemplifies the impact of innovation in medicine. His patents and collaborations reflect a commitment to improving patient outcomes through advanced therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile